0001209191-20-049990.txt : 20200910
0001209191-20-049990.hdr.sgml : 20200910
20200910164446
ACCESSION NUMBER: 0001209191-20-049990
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200910
FILED AS OF DATE: 20200910
DATE AS OF CHANGE: 20200910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YORDON JEFFREY
CENTRAL INDEX KEY: 0001189013
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 201169089
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-10
0
0001300699
Athenex, Inc.
ATNX
0001189013
YORDON JEFFREY
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO
NY
14203
0
1
0
0
See Remarks
Common Stock
2020-09-10
4
M
0
18180
11.00
A
237106
D
Stock Option (Right to Buy)
9.00
2018-06-19
2026-06-19
Common Stock
150000
150000
D
Stock Option (Right to Buy)
11.00
2020-09-10
4
M
0
18180
0.00
D
2020-06-13
2027-06-13
Common Stock
18180
211820
D
Stock Option (Right to Buy)
17.30
2028-03-27
Common Stock
100000
100000
D
Stock Option (Right to Buy)
13.17
2029-02-28
Common Stock
100000
100000
D
Stock Option (Right to Buy)
12.45
2030-06-05
Common Stock
100000
100000
D
This option vests in four equal annual installments beginning on March 27, 2019.
This option vests in four equal annual installments beginning on February 28, 2020.
This option vests in four equal annual installments beginning on June 5, 2021.
COO, and President, Athenex Pharmaceutical Division.
/s/ Teresa Bair, Attorney-in-Fact
2020-09-10